DiaSorin S.p.A.

Milan Stock Exchange DIA.MI

DiaSorin S.p.A. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD -32.12 M

DiaSorin S.p.A. Net Cash Used For Investing Activities is USD -32.12 M for the year ending December 31, 2023, a 87.06% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

DiaSorin S.p.A. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -248.17 M, a 86.47% change year over year.
DiaSorin S.p.A. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -1.83 B, a -1,956.11% change year over year.
DiaSorin S.p.A. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -89.20 M, a -34.44% change year over year.
DiaSorin S.p.A. Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -66.35 M, a 18.83% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

Milan Stock Exchange: DIA.MI

DiaSorin S.p.A.

CEO	Mr. Carlo Rosa
IPO Date	July 19, 2007
Location	Italy
Headquarters	Via Crescentino snc
Employees	3,184
Sector	Healthcare
Industries Biotechnology 3D Printing Medical Instruments Pharmaceuticals Vaccines

Description

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

Key trends

Past 5 years